Arvinas Releases Updated Dose Escalation Data from Clinical Trial of PROTAC® Protein Degrader ARV-110 in Patients with Metastatic ...
- Clear efficacy signal with two ongoing confirmed PSA responses, including one associated with a confirmed RECIST response - - Data represent the first demonstration of PROTAC®-mediated degradation of a disease-causing protein in humans - NEW HAVEN, Conn …